Literature DB >> 1009518

Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers.

F Arcamone, L Bernardi, P Giardino, B Patelli, A Marco, A M Casazza, G Pratesi, P Reggiani.   

Abstract

Four new derivatives of daunorubicin, characterized by the absence of the methoxyl group at the C-4 position, have been obtained by chemical synthesis. 4-Demethoxydaunorubicin (NSC-256439) was effective against L1210 and Gross leukemias and ascites and solid Sarcoma 180 at doses four to eight times lower than those effective for daunorubicin. The beta anomer of 4-demethoxydaunorubicin was active at doses 13and eight times higher than those of its corresponding alpha anomer against L1210 and Gross leukemias respectively. 4-Demethoxy-7,9-diepidaunorubicin and its beta anomer were devoid of any biologic activity at the doses tested.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1009518

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  40 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients.

Authors:  L Zanette; M Zucchetti; A Freshi; D Erranti; U Tirelli; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.

Authors:  M J Kuffel; J M Reid; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Phase II trial of idarubicin in patients with advanced lymphoma.

Authors:  H Gillies; R Liang; H Rogers; P Harper; L Parapia; G Cox; S Johnson
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 5.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 6.  Clinical pharmacokinetics of idarubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

7.  Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.

Authors:  F Formelli; A M Casazza; A Di Marco; A Mariani; C Pollini
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.

Authors:  H C Gillies; D Herriott; R Liang; K Ohashi; H J Rogers; P G Harper
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

9.  Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin.

Authors:  D B Smith; J M Margison; S B Lucas; P M Wilkinson; A Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.

Authors:  B J Cusack; S P Young; J Driskell; R D Olson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.